DE60019164D1 - N6 heterocyclische 8-modifizierte adenosinderivate - Google Patents

N6 heterocyclische 8-modifizierte adenosinderivate

Info

Publication number
DE60019164D1
DE60019164D1 DE60019164T DE60019164T DE60019164D1 DE 60019164 D1 DE60019164 D1 DE 60019164D1 DE 60019164 T DE60019164 T DE 60019164T DE 60019164 T DE60019164 T DE 60019164T DE 60019164 D1 DE60019164 D1 DE 60019164D1
Authority
DE
Germany
Prior art keywords
heterocyclic
adenosine derivatives
modified adenosine
modified
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019164T
Other languages
English (en)
Other versions
DE60019164T2 (de
Inventor
A Zablocki
P Palle
N Ibrahim
Luiz Belardinelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of DE60019164D1 publication Critical patent/DE60019164D1/de
Application granted granted Critical
Publication of DE60019164T2 publication Critical patent/DE60019164T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DE60019164T 1999-12-03 2000-11-29 N6 heterocyclische 8-modifizierte adenosinderivate Expired - Lifetime DE60019164T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US454485 1982-12-29
US09/454,485 US6294522B1 (en) 1999-12-03 1999-12-03 N6 heterocyclic 8-modified adenosine derivatives
PCT/US2000/042396 WO2001042265A2 (en) 1999-12-03 2000-11-29 N6 heterocyclic 8-modified adenosine derivatives

Publications (2)

Publication Number Publication Date
DE60019164D1 true DE60019164D1 (de) 2005-05-04
DE60019164T2 DE60019164T2 (de) 2006-02-02

Family

ID=23804799

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019164T Expired - Lifetime DE60019164T2 (de) 1999-12-03 2000-11-29 N6 heterocyclische 8-modifizierte adenosinderivate

Country Status (20)

Country Link
US (2) US6294522B1 (de)
EP (1) EP1237898B1 (de)
JP (1) JP4021196B2 (de)
KR (1) KR100484987B1 (de)
CN (1) CN1195772C (de)
AR (1) AR029198A1 (de)
AT (1) ATE292140T1 (de)
AU (1) AU771242B2 (de)
CA (1) CA2394861C (de)
DE (1) DE60019164T2 (de)
ES (1) ES2236044T3 (de)
HK (1) HK1051695B (de)
IL (2) IL149651A0 (de)
MX (1) MXPA02005318A (de)
NO (1) NO323138B1 (de)
NZ (1) NZ518736A (de)
TR (1) TR200201470T2 (de)
TW (1) TWI268923B (de)
WO (1) WO2001042265A2 (de)
ZA (1) ZA200204379B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171032A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
US20050118605A9 (en) * 1996-06-06 2005-06-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20040161844A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US20040161777A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Modified oligonucleotides for use in RNA interference
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
AU2001238665A1 (en) * 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
IL163613A0 (en) * 2002-02-19 2005-12-18 Cv Therapeutics Inc Partial and full agonists of a1 adenosine receptors
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
CN1671399A (zh) * 2002-07-29 2005-09-21 Cv医药有限公司 利用a2a受体激动剂的心肌灌注显像
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP1562971B1 (de) * 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polyzyklischen zuckerersatz beinhaltende oligomere verbindungen und zusammensetzungen zur verwendung bei der genmodulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US20070161582A1 (en) * 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
PL1682537T3 (pl) * 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
CA2580236A1 (en) * 2004-09-17 2006-03-23 Kissei Pharmaceutical Co., Ltd. Purinenucleoside derivative modified in 8-position and medical use thereof
CA2583185A1 (en) 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
CA2609053C (en) * 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
EP2581381A3 (de) * 2006-02-03 2013-10-30 Gilead Sciences, Inc. Verfahren zur Herstellung eines A2A-Adenosin-Rezeptor-Agonisten und seiner Polymorphe
JP2009541354A (ja) * 2006-06-22 2009-11-26 シーブイ・セラピューティクス・インコーポレイテッド 虚血の治療におけるa2aアデノシン受容体アゴニストの使用
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008028140A1 (en) * 2006-09-01 2008-03-06 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
WO2008086096A2 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
EP3797775A1 (de) 2007-10-19 2021-03-31 Novartis AG Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
EP3632444A3 (de) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topische lfa-1-antagonisten zur verwendung in der lokalen behandlung von immunerkrankungen
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化lfa−1アンタゴニスト
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
JP2012504147A (ja) * 2008-09-29 2012-02-16 ギリアード サイエンシーズ, インコーポレイテッド 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびA−2−α受容体作動薬の組み合わせ
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物
CZ308881B6 (cs) * 2014-12-09 2021-08-04 Univerzita Palackého v Olomouci 6-aryl-9-glykosylpuriny a jejich použití
GB201820685D0 (en) * 2018-12-19 2019-01-30 NuCana plc Synthesis of 8-chloroadenosine derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2881164A (en) * 1955-07-18 1959-04-07 American Cyanamid Co Ribofuranosyl derivatives of 6-aralkylamino and 6-heterocyclicalkylaminopurines
US3150124A (en) * 1962-03-16 1964-09-22 Svarnas George Synthesis of kinetin glycosides
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
US4616003A (en) * 1984-10-26 1986-10-07 Warner-Lambert Company N6 -dihydroxypropyladenosines
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
US5236902A (en) * 1990-11-26 1993-08-17 The Governors Of The University Of Alberta Method and probes for detecting nucleoside transporter and method for producing the probes
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
WO1993021929A1 (en) * 1992-05-01 1993-11-11 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phosphorothioate derivatives of cyclic amp analogues
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
JPH07324035A (ja) * 1994-05-30 1995-12-12 L T T Kenkyusho:Kk 滑膜細胞増殖抑制剤及び慢性関節リウマチ治療剤
EP0764639A4 (de) 1994-06-09 1997-10-01 Ss Pharmaceutical Co 4-chinolinonderivat oder dessen salz
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AR029198A1 (es) 2003-06-18
WO2001042265A3 (en) 2002-01-03
NO20022573L (no) 2002-05-30
KR20030032906A (ko) 2003-04-26
CA2394861A1 (en) 2001-06-14
HK1051695A1 (en) 2003-08-15
AU4510101A (en) 2001-06-18
JP2003516413A (ja) 2003-05-13
AU771242B2 (en) 2004-03-18
JP4021196B2 (ja) 2007-12-12
HK1051695B (zh) 2005-06-03
EP1237898B1 (de) 2005-03-30
TR200201470T2 (tr) 2002-12-23
CN1195772C (zh) 2005-04-06
CN1402732A (zh) 2003-03-12
DE60019164T2 (de) 2006-02-02
TWI268923B (en) 2006-12-21
NO20022573D0 (no) 2002-05-30
US20020045595A1 (en) 2002-04-18
WO2001042265A2 (en) 2001-06-14
CA2394861C (en) 2007-01-30
ATE292140T1 (de) 2005-04-15
ZA200204379B (en) 2003-06-25
IL149651A (en) 2006-08-20
KR100484987B1 (ko) 2005-04-22
NO323138B1 (no) 2007-01-08
NZ518736A (en) 2004-02-27
MXPA02005318A (es) 2002-12-11
ES2236044T3 (es) 2005-07-16
EP1237898A2 (de) 2002-09-11
US6294522B1 (en) 2001-09-25
IL149651A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
ATE292140T1 (de) N6 heterocyclische 8-modifizierte adenosinderivate
ATE321065T1 (de) Purin-derivate
ATE238336T1 (de) Purin-derivate
NO20016109L (no) Purinderivater
NO20010743D0 (no) Antivirale indoloksoacetyl-piperazin-derivater
DE60009747D1 (de) Admantan-derivate
ATE277941T1 (de) Adenosinderivate
DE50010060D1 (de) Thiazolylamid-derivate
DE50013404D1 (de) Substituierte 2-dialkylaminoalkylbiphenyl-derivate
ATE257148T1 (de) Propargyletherderivate
ATE273272T1 (de) Mevinolinderivate
ATE293592T1 (de) Resorcinderivate
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DE60001736T2 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
NO20022682D0 (no) Heterosykliske derivater
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
TH109999B (th) นิวคลีโอไซด์

Legal Events

Date Code Title Description
8364 No opposition during term of opposition